Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension.

Levy M, Celermajer DS, Bourges-Petit E, Del Cerro MJ, Bajolle F, Bonnet D.

J Pediatr. 2011 Apr;158(4):584-8. doi: 10.1016/j.jpeds.2010.09.025. Epub 2010 Oct 30.

PMID:
21035821
2.

Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.

Ivy DD, Rosenzweig EB, Lemarié JC, Brand M, Rosenberg D, Barst RJ.

Am J Cardiol. 2010 Nov 1;106(9):1332-8. doi: 10.1016/j.amjcard.2010.06.064.

3.

Tadalafil for the treatment of pulmonary arterial hypertension.

Rosenzweig EB.

Expert Opin Pharmacother. 2010 Jan;11(1):127-32. doi: 10.1517/14656560903413542. Review.

PMID:
20001434
4.

Tadalafil therapy for pulmonary arterial hypertension.

Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group..

Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Erratum in: Circulation. 2011 Sep 6;124(10):e279. Dosage error in article text.

5.

Pulmonary arterial hypertension.

Chin KM, Rubin LJ.

J Am Coll Cardiol. 2008 Apr 22;51(16):1527-38. doi: 10.1016/j.jacc.2008.01.024. Review. Erratum in: J Am Coll Cardiol. 2008 Jul 8;52(2):169.

6.

Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.

Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, Brady D, Law Y, Parker D, Claussen L, Abman SH.

J Am Coll Cardiol. 2008 Jan 15;51(2):161-9. doi: 10.1016/j.jacc.2007.09.031.

7.
8.

Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.

Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N, Trehan V, Tyagi S.

Circulation. 2006 Oct 24;114(17):1807-10. Epub 2006 Oct 9.

9.

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.

Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators..

Circulation. 2006 Jul 4;114(1):48-54. Epub 2006 Jun 26.

10.
11.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group..

N Engl J Med. 2005 Nov 17;353(20):2148-57. Erratum in: N Engl J Med. 2006 Jun 1;354(22):2400-1.

12.
13.

Outcomes in children with idiopathic pulmonary arterial hypertension.

Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ.

Circulation. 2004 Aug 10;110(6):660-5. Epub 2004 Aug 2.

14.

A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.

von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, Lockhart D, Beasley CM Jr, Emmick JT.

Eur Urol. 2004 Apr;45(4):499-507; discussion 507-9.

PMID:
15041116
15.

Beraprost therapy for pulmonary arterial hypertension.

Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R; Beraprost Study Group..

J Am Coll Cardiol. 2003 Jun 18;41(12):2119-25. Erratum in: J Am Coll Cardiol. 2003 Aug 6;42(3):591.

16.

Primary pulmonary hypertension.

Rubin LJ.

N Engl J Med. 1997 Jan 9;336(2):111-7. Review. No abstract available.

PMID:
8988890

Supplemental Content

Support Center